deltatrials
Unknown PHASE3 INTERVENTIONAL 2-arm NCT02743923

Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

Chemotherapy in KRAS Mutated Chemotherapy Naive Non-small Cell Lung Cancer Patients: a Phase III Study Comparing Cisplatin-pemetrexed With Carboplatin-paclitaxel-bevacizumab: NVALT 22

Sponsor: Dutch Society of Physicians for Pulmonology and Tuberculosis

Conditions Carcinoma, Non-Small Cell Lung
Interventions Bevacizumab Pemetrexed carboplatin cisplatin paclitaxel
Updated 17 times since 2017 Last updated: Dec 6, 2021 Started: Apr 30, 2016 Primary completion: Sep 19, 2021 Completion: Apr 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Carcinoma, Non-Small Cell Lung and is currently ongoing. Dutch Society of Physicians for Pulmonology and Tuberculosis leads this study, which shows 17 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Jan 2018 · 3 months · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Sep 2020 · 21 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~May 2024 · 28 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  4. May 2024 — Jul 2024 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  5. Jan 2022 — May 2024 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

▶ Show 12 earlier versions

  1. Jan 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  2. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  3. Dec 2018 — Sep 2020 [monthly]

    Recruiting PHASE3

  4. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  5. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  6. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  7. Jan 2018 — Mar 2018 [monthly]

    Recruiting PHASE3

  8. Oct 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  9. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  10. May 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  11. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Apr 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dutch Society of Physicians for Pulmonology and Tuberculosis
  • The Netherlands Cancer Institute
Data source: The Netherlands Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Almelo, Netherlands , Amersfoort, Netherlands , Amsterdam, Netherlands , Apeldoorn, Netherlands , Breda, Netherlands , Deventer, Netherlands , Dordrecht, Netherlands , Ede, Netherlands , Eindhoven, Netherlands and 12 more locations